Sept 2 - Marlboro-maker Altria initiated legal action against the U.S. Food and Drug Administration on Wednesday, asking a federal court to compel the agency to replace the current tobacco product review process with a new system, court documents show.
In its complaint filed in federal court in Lubbock, Texas, Altria argues the FDA's existing application pathway for new tobacco products has impeded the market entry of newer nicotine offerings. Under U.S. law, the FDA must review applications for new tobacco products before they are permitted for sale, evaluating whether an application demonstrates a net public health benefit - for example, by helping cigarette smokers quit.
Altria's filing singles out its On! nicotine pouches as an example of products that have been delayed by what the company describes as regulatory red tape. The lawsuit contends that while these products have been caught up in the agency's review procedures, some foreign competitors that did not follow the same rules have been able to increase their market share.
The company has requested that the court set aside the current review system and order the FDA to develop a replacement framework. Among the legal arguments presented, Altria asserts the FDA is violating a statutory requirement that the agency must decide on applications within 180 days of receipt - a deadline Altria says the FDA has never met.
The complaint frames the dispute as a procedural and statutory objection to how the agency administers its review responsibilities rather than as an attack on the statutory standard itself. Altria is seeking judicial relief to force a change in how the FDA processes and decides tobacco product applications.
The filing notes market consequences Altria attributes to the agency's approach, including lost opportunity for its On! nicotine pouches to compete effectively in the U.S. while noncompliant foreign rivals expanded their presence. The company asked the court to require an overhaul of the system so that products can be reviewed and decided upon in a manner consistent with statutory timelines.
The FDA did not immediately respond to a request for comment.
Clear summary
Altria has sued the FDA in federal court in Lubbock, Texas, seeking a judicial order to set aside the agency's current tobacco product review process and to require creation of a new system. The company says the existing approach has delayed products such as its On! nicotine pouches from reaching the U.S. market and that the FDA has failed to meet a statutory 180-day decision deadline on applications.
Context and implications
- Altria focuses its complaint on process failures it attributes to the FDA's handling of new tobacco product applications and on competitive dynamics tied to noncompliant foreign entrants.
- The company seeks a court order requiring the agency to design a new review system and to adhere to statutory decision timelines.
- The dispute centers on administrative procedure and statutory timing rather than on the statutory standards used to judge public health benefit.